je.st
news
Tag: fda merck
Merck & Co. Wins U.S. FDA Approval of New Type of Sleeping Pill
2014-08-14 09:59:54| Biotech - Topix.net
Merck & Co., the second-largest U.S. drugmaker, won approval to sell its treatment for insomnia, a new type of drug considered to have fewer side effects than older pills such as Ambien.
U.S. FDA approves Merck blood clot preventer
2014-05-09 16:22:54| Biotech - Topix.net
U .S. health regulators on Thursday approved a blood clot preventer developed by Merck & Co for use by patients who have had a heart attack or who suffer from blockages in the arteries of the legs.
Tags: blood
fda
approves
merck
Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma
2014-05-06 14:40:00| Merck.com - Corporate News
Dateline City: BOSTON Priority Review Designation for MK-3475 BLA for Proposed Indication of Unresectable or Metastatic Melanoma in Patients Who Have Been Previously Treated with Ipilimumab Advancing New Phase 3 Studies with MK-3475 in Adjuvant Melanoma, Previously-Untreated Non-Small Cell Lung Cancer, Advanced Head & Neck and Bladder Cancers Data from Studies in Three Different Cancer Types to be presented at 2014 ASCO Annual Meeting Initiating Phase 1 Study with Investigational Anti-GITR Antibody (MK-4166) BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-3475, Mercks investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab. Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license
FDA OKs Merck Tablet to Reduce Ragweed Allergies
2014-04-18 00:15:25| Biotech - Topix.net
U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen.
Tags: reduce
tablet
fda
allergies
Merck Statement on FDA Advisory Committee Meeting for RAGWITEK (Short Ragweed Pollen Allergen Extract), an Investigational Sublingual Allergy Immunotherapy Tablet
2014-01-29 03:26:07| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said it was pleased with the positive discussion of RAGWITEK (Short Ragweed Pollen Allergen Extract) at the Allergenic Products Advisory Committee meeting of the U.S. Food and Drug Administration (FDA). Language: English read more
Tags: short
statement
meeting
committee